Evidence map›Paper›PMID 40353471›Full record

ArticleCurrent radiopharmaceuticals2025

[

Michela Cossandi, Massimo Statuto, Giorgio Biasiotto, Gian Luca Vigano, Luca Camoni, Elena Migliorati, Carlo Rodella, Federica Saiani, Luigi Spiazzi, Francesco Bertagna

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michela CossandiNuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Massimo StatutoNuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Giorgio BiasiottoHighly Specialized Laboratory, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
Gian Luca ViganoClinical Engineering, ASST Spedali Civili di Brescia, Brescia, Italy.
Luca CamoniNuclear Medicine, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy.
Elena MiglioratiNuclear Medicine, ASST Spedali Civili di Brescia, Brescia, Italy.
Carlo RodellaHealth Physics, ASST Spedali Civili, Brescia, Italy.
Federica SaianiHealth Physics, ASST Spedali Civili, Brescia, Italy.
Luigi SpiazziHealth Physics, ASST Spedali Civili, Brescia, Italy.
Francesco BertagnaNuclear Medicine, ASST Spedali Civili di Brescia and University of Brescia, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction[

methodsThe production of [

results[ DISCUSSION: The main issues, their causes and the strategies used to solve them are reported in the troubleshooting section: thanks to these strategies, the number of failed syntheses has decreased, and today, we have achieved a 0% failure rate.

conclusionLiquid target production of [

Indexed as

CyclotronsGallium RadioisotopesOctreotideOrganometallic CompoundsRadiopharmaceuticalsHumansItalyNeuroendocrine TumorsPositron Emission Tomography Computed TomographyGa(III)-DOTATOCGallium-68Gallium RadioisotopesOctreotideOrganometallic CompoundsRadiopharmaceuticals[68Ga]Ga-DOTA-TOCCyclotroneuropean pharmacopeia.gastroenteropancreatic neuroendocrine tumorsgeneratorliquid targetpositron emission tomographyradiopharmaceutical

Identifiers

PMID40353471
PMCPMC12376115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.